Recuro Health Acquires MyLifeIQ to Accelerate Precision Medicine

Recuro Health, a digital virtual care platform, acquired MyLifeIQ, an epigenetics and precision medicine platform. The terms of the acquisition were not disclosed.

MyLifeIQ precision medicine platform captures data and delivers the uniqueness of each person, pulling together the variables involved in health, including DNA, wearable data, and lifestyle assessments.

Recently, Recuro Health, announced the acquisition of SupDoc, an AI-enabled virtual health solution for care delivery. The financial terms of the acquisition were not disclosed.

Recuro offers a cloud-based virtual care platform with a curated suite of digital solutions – from primary care and behavioral health to at-home testing and genetic screening. According to the company, these digital solutions allow patients to engage with physicians, receive more personalized care, and monitor their health.

In August – Recuro Health announced a $15 million Series A financing round. ARCH Venture Partners led the round with follow-on support from OLSF Ventures, Cortado Ventures, 1843 Capital, and Sage Venture Partners. Telehealth companies raised a record $5 billion in 1H 2021, a 150% increase year-over-year compared to $2 billion raised in 1H 2020.

Michael Gorton, CEO, and founder of Recuro Health said, “In response to the needs of self-insured employers seeking digital solutions that improve employee health and productivity, we’re taking genomics to the next level of utility. This genomics solution creates an information platform that people can use on a daily basis, building an inimitable health and personalized medicine profile that is truly a life picture of one person and his or her distinctive health portrait. This is an opportunity to get clarity and transform health information into action.”

One hundred thirty-six digital health companies were acquired in the first half of 2021 compared to 83 in 1H 2020, according to the latest Mercom Digital Health Funding and M&A Report.